Capricor Faces Fraud Suit Over Dermamiocel Data

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is the subject of a securities fraud class action filed by Kaplan Fox & Kilsheimer LLP. The lawsuit targets investors who acquired company securities between December 17, 2025, and July 26, 2026. The core allegation centers on the company's handling of data for its resubmitted Dermamiocel Biologics License Application. According to the complaint, Capricor altered its pre-specified statistical analysis plan without prior regulatory review or agreement from the FDA.

The legal action was prompted by events on July 27, 2026, when the FDA released briefing documents ahead of an Advisory Committee meeting. These documents indicated that the final statistical plan had not been submitted to the FDA for review before the biologic license application was filed. Following this disclosure, Capricor shares dropped $12.70, a 64% decline, to close at $7 per share. Investors seeking to lead the class action have until September 28, 2026, to file a motion with the court, as reported by GN stocks/nasdaq.

Regulatory Disclosure Triggers Market Drop

The complaint details a specific sequence of events that led to the financial loss. On the morning of July 27, 2026, before market open, the FDA published briefing materials for its review of Capricor’s Dermamiocel resubmission. The materials revealed that the company had modified its statistical analysis plan, a critical component for demonstrating drug efficacy. The final version of this plan was never submitted to the FDA for pre-review, nor was it agreed upon by regulators, contradicting standard submission protocols.

The market reacted immediately to this regulatory transparency. Capricor’s stock price fell from its previous close to $7.00, erasing significant market value in a single session. The lawsuit argues that this price collapse was a direct result of the company's failure to accurately represent the status of its regulatory submissions and statistical methodologies to the public during the class period.

Lead Plaintiff Deadline Approaches

Investors who purchased Capricor shares during the specified class period are eligible to participate in the lawsuit. Kaplan Fox & Kilsheimer LLP advises that any member of the proposed class may move the court to serve as the lead plaintiff. The deadline to submit such a motion is September 28, 2026. Participation in the class action does not require an individual to seek the lead plaintiff position; however, that role carries greater responsibility in directing the litigation strategy.

The firm, which has been active in securities litigation since 1956, encourages affected parties to review their holdings. The lawsuit seeks to address alleged misrepresentations regarding the company's clinical data integrity. Investors are advised to consult legal counsel to understand their rights and potential recovery options under federal securities laws.

Firm Background and Litigation History

Kaplan Fox & Kilsheimer LLP is a plaintiffs' law firm with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. The firm focuses on complex litigation, including securities, antitrust, and consumer protection matters. It reports having recovered over $10 billion for clients and represented classes in various federal and state courts across the United States.

The firm’s portfolio includes high-profile recoveries such as a $2.425 billion settlement for Bank of America shareholders and an $800 million recovery for the Arkansas Teacher Retirement System. These cases underscore the firm's experience in handling large-scale securities disputes. Contact information for the firm is available for investors seeking further details on the Capricor litigation.